** Shares in Ion Beam Applications IBAB.BR rise 4.3% after
the Belgian healthcare firm announced it would partner with
Framatome to develop cyclotron network
** The two companies will collaborate on building a
Astatine-211 network in Europe and the U.S. with IBA
contributing specialised equipment
** "We do like IBA expanding the potential addressable
market for its cyclotrons", ING analysts say in a note, adding
it could leverage technological competitive edge to gain more
value chain in a new industry
** ING adds that the Astatine product would complement, not
compete, with firm's radioisotope Actinium, as it can have other
type of cancer treatment application
** Astatine is a radioisotope currently being investigated
for its potential in targeted alpha-therapeutic approaches in
oncology
(Reporting by Mateusz Rabiega)
((Mateusz.rabiega@thomsonreuters.com;))